Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
NBTX Stock Forecast 2026-2027
$31.52
Current Price
$1.53B
Market Cap
Buy 6
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to NBTX Price Targets
+3.1%
To High Target of $32.50
-18.0%
To Median Target of $25.84
-20.7%
To Low Target of $25.00
NBTX Price Momentum
-7.3%
1 Week Change
+24.4%
1 Month Change
+872.8%
1 Year Change
+36.3%
Year-to-Date Change
-24.8%
From 52W High of $41.89
+955.6%
From 52W Low of $2.99
📊 TOP ANALYST CALLS
Did NBTX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Nanobiotix is one of their latest high-conviction picks.
Latest NBTX Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, NBTX has a bullish consensus with a median price target of $25.84 (ranging from $25.00 to $32.50). The overall analyst rating is N/A (N/A/10). Currently trading at $31.52, the median forecast implies a -18.0% downside. This outlook is supported by 6 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NBTX Analyst Ratings
6
Buy
0
Hold
0
Sell
NBTX Price Target Range
Low
$25.00
Average
$25.84
High
$32.50
Current: $31.52
Latest NBTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NBTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 6, 2026 | Guggenheim | Michael Schmidt | Buy | Maintains | $26.00 |
| Apr 4, 2025 | Guggenheim | Michael Schmidt | Buy | Maintains | $8.00 |
| Aug 28, 2024 | Guggenheim | Michael Schmidt | Buy | Initiates | $12.00 |
| Dec 8, 2023 | Leerink Partners | Jonathan Chang | Outperform | Initiates | $11.00 |
| Jan 6, 2021 | Evercore ISI Group | Jonathan Miller | Outperform | Initiates | $N/A |
Nanobiotix S.A. American Depositary Shares (NBTX) Competitors
The following stocks are similar to Nanobiotix based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Nanobiotix S.A. American Depositary Shares (NBTX) Financial Data
Nanobiotix S.A. American Depositary Shares has a market capitalization of $1.53B with a P/E ratio of -24.5x. The company generates $11.82M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +186.8% quarter-over-quarter, while maintaining an operating margin of +3.1% and return on equity of +103.7%.
Valuation Metrics
Market Cap
$1.53B
Enterprise Value
$2.19B
P/E Ratio
-24.5x
PEG Ratio
124.4x
Price/Sales
184.1x
Growth & Margins
Revenue Growth (YoY)
+186.8%
Gross Margin
N/A
Operating Margin
+3.1%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+1.9%
Current Ratio
0.6x
Debt/Equity
-0.9x
ROE
+103.7%
ROA
-41.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Nanobiotix S.A. American Depositary Shares (NBTX) Business Model
About Nanobiotix S.A. American Depositary Shares
What They Do
Develops innovative cancer treatment solutions through nanomedicine.
Business Model
Nanobiotix makes money by developing and commercializing its proprietary NanoXray platform, which enhances the efficacy of radiotherapy for cancer treatment. The company operates through American Depositary Receipts (ADRs), allowing U.S. investors to easily invest in its growth potential.
Additional Information
Nanobiotix is at the forefront of biotechnology, focusing on improving patient outcomes in solid tumors and potentially redefining cancer treatment protocols. The company's advancements reflect a global trend in innovative cancer therapies and underline its critical role in transforming therapeutic approaches in oncology.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
108
CEO
Mr. Laurent Levy Ph.D.
Country
France
IPO Year
2020
Website
www.nanobiotix.comNanobiotix S.A. American Depositary Shares (NBTX) Latest News & Analysis
Latest News
Quick Summary
The news excerpt references compliance with specific articles of the French Commercial Code and regulations from the French Financial Markets Authority, indicating adherence to legal standards.
Why It Matters
The excerpt indicates regulatory compliance, signaling transparency and governance standards, which can enhance investor confidence and potentially influence stock valuations.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
NANOBIOTIX will participate in upcoming conferences in March 2026, focusing on their nanotherapeutic approaches for cancer treatment.
Why It Matters
NANOBIOTIX's participation in key conferences signals potential advancements in cancer treatment, which may attract investor interest and impact its stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Nanobiotix has been admitted to the CAC Mid 60 and SBF 120 indices following the annual review by the Euronext Paris indices, enhancing its market visibility.
Why It Matters
Nanobiotix's inclusion in the CAC Mid 60 and SBF 120 indices enhances its visibility and credibility, potentially attracting more institutional investment and driving stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Biotech Stock Nanobiotix (NBTX) Is Up 660% This Year -- Here's Why the Rally Could Continue
3 months ago
Quick Summary
Nanobiotix, a French biotechnology firm, has obtained financing from Johnson & Johnson and other sources, indicating investor confidence in its growth potential.
Why It Matters
Nanobiotix's financing from Johnson & Johnson indicates investor confidence and potential for growth, which can enhance its market value and attract further investments.
Source: The Motley Fool
Market Sentiment:
Positive
Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook
3 months ago
Quick Summary
Nanobiotix reported Q3 2025 operational and financial results, highlighting upcoming clinical updates in 2026 and the completion of a non-dilutive royalty financing with HCRx.
Why It Matters
Nanobiotix's operational update and financial results, alongside anticipated clinical developments and successful financing, indicate potential growth and innovation in cancer treatment, impacting investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Nanobiotix has announced advancements in its Curadigm Nanoprimer platform, focusing on innovative physics-based cancer treatment approaches.
Why It Matters
Advancements in NANOBIOTIX's Curadigm Nanoprimer platform could enhance treatment options, potentially driving stock value and investor interest in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About NBTX Stock
What is Nanobiotix S.A. American Depositary Shares's (NBTX) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, Nanobiotix S.A. American Depositary Shares (NBTX) has a median price target of $25.84. The highest price target is $32.50 and the lowest is $25.00.
Is NBTX stock a good investment in 2026?
According to current analyst ratings, NBTX has 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $31.52. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NBTX stock?
Wall Street analysts predict NBTX stock could reach $25.84 in the next 12 months. This represents a -18.0% decrease from the current price of $31.52. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Nanobiotix S.A. American Depositary Shares's business model?
Nanobiotix makes money by developing and commercializing its proprietary NanoXray platform, which enhances the efficacy of radiotherapy for cancer treatment. The company operates through American Depositary Receipts (ADRs), allowing U.S. investors to easily invest in its growth potential.
What is the highest forecasted price for NBTX Nanobiotix S.A. American Depositary Shares?
The highest price target for NBTX is $32.50 from at , which represents a 3.1% increase from the current price of $31.52.
What is the lowest forecasted price for NBTX Nanobiotix S.A. American Depositary Shares?
The lowest price target for NBTX is $25.00 from at , which represents a -20.7% decrease from the current price of $31.52.
What is the overall NBTX consensus from analysts for Nanobiotix S.A. American Depositary Shares?
The overall analyst consensus for NBTX is bullish. Out of 3 Wall Street analysts, 6 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $25.84.
How accurate are NBTX stock price projections?
Stock price projections, including those for Nanobiotix S.A. American Depositary Shares, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 13, 2026 2:14 PM UTC